His primary areas of study are Immunology, Internal medicine, Melanoma, Immunotherapy and Talimogene laherparepvec. His Immunology study combines topics in areas such as Cancer and Vaccinia. His research integrates issues of Gastroenterology, Surgery and Oncology in his study of Internal medicine.
His work investigates the relationship between Melanoma and topics such as Ipilimumab that intersect with problems in Hydroxychloroquine, Autoimmune disease, Rheumatoid arthritis, Prednisone and CTLA-4. His biological study deals with issues like ELISPOT, which deal with fields such as ALVAC Vaccine, MART-1 Antigen, CD80 and Tumor microenvironment. The Talimogene laherparepvec study combines topics in areas such as Granulocyte macrophage colony-stimulating factor and Oncolytic virus.
The scientist’s investigation covers issues in Immunotherapy, Internal medicine, Oncology, Immunology and Melanoma. His Immunotherapy research incorporates themes from Cancer research, Oncolytic virus and Virology. His study looks at the intersection of Internal medicine and topics like Surgery with Gastroenterology and Adverse effect.
His Overall survival study, which is part of a larger body of work in Oncology, is frequently linked to In patient, bridging the gap between disciplines. Immunology is closely attributed to Vaccinia in his research. As part of one scientific family, Howard L. Kaufman deals mainly with the area of Melanoma, narrowing it down to issues related to the Talimogene laherparepvec, and often Unresected and Stage iiib.
His primary areas of study are Internal medicine, Oncology, Immunotherapy, Cancer research and Melanoma. His Oncology research includes elements of Avelumab, Nivolumab and Surgery. He is conducting research in Cancer and Immunology as part of his Immunotherapy study.
His Cancer research focuses on Immune system and how it connects with Breast cancer. His Melanoma study combines topics from a wide range of disciplines, such as Gastroenterology, Talimogene laherparepvec, CD8 and Oncolytic virus. Howard L. Kaufman interconnects Oncolytic Virus Therapy and Ipilimumab in the investigation of issues within Talimogene laherparepvec.
His main research concerns Immunotherapy, Melanoma, Internal medicine, Cancer and Cancer research. His research integrates issues of Virus, Oncolytic virus, Tumor Cell Biology and Pandemic in his study of Immunotherapy. The Oncolytic virus study combines topics in areas such as Targeted therapy, Talimogene laherparepvec and Immunogenicity.
His Internal medicine research is multidisciplinary, relying on both Surgery and Oncology. In his study, Metastatic melanoma and Clinical study design is strongly linked to Immunology, which falls under the umbrella field of Oncology. His Cancer study integrates concerns from other disciplines, such as Adverse effect, Clinical trial and Immune system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda.
Journal of Clinical Oncology (2015)
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry.
The New England Journal of Medicine (2011)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman;Frederick J. Kohlhapp;Andrew Zloza.
Nature Reviews Drug Discovery (2015)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia.
Lancet Oncology (2016)
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham.
Journal for ImmunoTherapy of Cancer (2017)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis.
Journal of Clinical Oncology (2009)
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Howard L. Kaufman;Dae Won Kim;Gail DeRaffele;Josephine Mitcham.
Annals of Surgical Oncology (2010)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino.
JAMA Oncology (2016)
Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
Giovanni C. Cesana;Gail DeRaffele;Seth Cohen;Dorota Moroziewicz.
Journal of Clinical Oncology (2006)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov;Mohammed M. Milhem;David Minor;Omid Hamid.
Journal of Clinical Oncology (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: